Six compounds, namely GW574783B, GW576924A, GW580496A, GW616030X, GW621823A, and GW633459A, are 4-anilino-quinazolines that bear a strong structural resemblance to lapatinib, used to treat breast cancer by targeting the human epidermal growth factor receptor (EGFR)/(HER) family (Supplementary Table S3; Figure 1D) (Lackey, 2006; Petrov et al., 2006; Qiu et al., 2008). Here, EGFR is linked to breast carcinoma.